BGB-283 Deemed Effective in Phase I Study [News in Brief]

In a phase I trial, BGB-283, which targets the RAF family of proteins, was found to be safe and tolerable—and effective—in treating patients with a variety of solid tumors harboring mutations in BRAF, KRAS, and NRAS.

from Cancer via ola Kala on Inoreader http://ift.tt/29kndbD
via IFTTT